Therapeutic options in pediatric non alcoholic fatty liver disease: Current status and future directions

Italian Journal of Pediatrics

Volumn 38, Issue 1, 2012, Pages

  Vajro, Pietro ^a,b   Lenta, Selvaggia ^c   Pignata, Claudio ^c   Salerno, Mariacarolina ^c   D'Aniello, Roberta ^a,b   De Micco, Ida ^c   Paolella, Giulia ^a,b   Parenti, Giancarlo ^c  

^a UNIVERSITY OF SALERNO   (Italy)

^b ELFID   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Children; Non alcoholic fatty liver disease; Therapy

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIOXIDANT; FARNESOID X RECEPTOR; INSULIN SENSITIZING AGENT; OMEGA 3 FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; URSODEOXYCHOLIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; CHILD; CHILDHOOD DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIFESTYLE MODIFICATION; LIVER; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; REVIEW; WEIGHT REDUCTION;

ANTIOXIDANTS; BARIATRIC SURGERY; CHILD; CHOLAGOGUES AND CHOLERETICS; FATTY ACIDS, OMEGA-3; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; OBESITY; OVERWEIGHT; PREBIOTICS; PROBIOTICS; URSODEOXYCHOLIC ACID; WEIGHT LOSS;

EID: 84867443178     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-38-55     Document Type: Review

References (52)

1. American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, Gastroenterology 2012 142 1592 1609 10.1053/j.gastro.2012.04.001 22656328
2. Dietary therapy for obesity: an emperor with no clothes. Mark AL, Hypertension 2008 51 1426 1434 10.1161/HYPERTENSIONAHA.106.085944 18474832
3. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H, J Pediatr Gastroenterol Nutr 2009 48 587 596 10.1097/MPG.0b013e31818e04d1 19412008
4. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT, Obesity (Silver Spring) 2009 17 2162 2168 10.1038/oby.2009.126
5. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-upstudy. Reinehr T, Schmidt C, Toschke AM, Andler W, Arch Dis Child 2009 94 437 442 10.1136/adc.2008.143594 19224892
6. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Koot BG, van der Baan-Slootweg OH, Tamminga-Smeulders CL, Rijcken TH, Korevaar JC, van Aalderen WM, Jansen PL, Benninga MA, Arch Dis Child 2011 96 669 674 10.1136/adc.2010.199760 21518734
7. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A, J Pediatr 1994 125 239 241 10.1016/S0022-3476(94)70202-0 8040771 (Pubitemid 24253007)
8. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A, Dig Dis Sci 1997 42 1428 1432 10.1023/A:1018850223495 9246041 (Pubitemid 27339358)
9. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM, Nonalcoholic Steatohepatitis Clinical Research Network, Hepatology 2010 51 1961 1971 10.1002/hep.23535 20301112
10. Long term nutritional intake and the risk for Non-alcoholic fatty liver disease (NAFLD) a population based study. ZelberSagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, Oren R, J Hepatol 2007 47 711 717 10.1016/j.jhep.2007.06.020 17850914 (Pubitemid 47503432)
11. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni C, Arch Dis Child 2011 96 350 353 10.1136/adc.2010.192401 21233083
12. Consensus Statement: Childhood Obesity for Pediatric Gastroenterologists. Huang JS, Barlow SE, Quiros-Tejeira RE, Scheimann A, Skelton J, Suskind D, Tsai P, Uko V, Warolin JP, Xanthakos SA, The NASPGHAN Obesity Task Force, J Pediatr Gastroenterol Nutr 2012 Epub ahead of print
13. Role of dietary factors and food habits in the development of childhood obesity: a commentary by the ESPGHAN Committee on Nutrition. Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, Mihatsch W, Moreno LA, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J, ESPGHAN Committee on Nutrition, J Pediatr Gastroenterol Nutr 2011 52 662 669 10.1097/MPG.0b013e3182169253 21593641
14. Risk factors for liver steatosis in obese children and adolescents. Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC, Pediatr Neonatol 2010 51 149 154 10.1016/S1875-9572(10)60028-9 20675238
15. Using nature and outdoor activity to improve children's health. McCurdy LE, Winterbottom KE, Mehta SS, Roberts JR, Curr Probl Pediatr Adolesc Health Care 2010 40 102 117 10.1016/j.cppeds.2010.02.003 20381783
16. Increased physical activity decreases hepatic free fatty acid uptake: a study in human monozygotic twins. Hannukainen JC, Nuutila P, Borra R, Kaprio J, Kujala UM, Janatuinen T, Heinonen OJ, Kapanen J, Viljanen T, Haaparanta M, Rönnemaa T, Parkkola R, Knuuti J, Kalliokoski KK, J Physiol 2007 578 347 358 17053033 (Pubitemid 44971131)
17. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R, J Clin Endocrinol Metab 2005 90 3191 3196 10.1210/jc.2004-1959 15769987 (Pubitemid 41014274)
18. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Van Der Heijden GJ, Wang ZJ, Chu Z, Toffolo G, Manesso E, Sauer PJ, Sunehag AL, Med Sci Sports Exerc 2010 42 1973 1980 10.1249/MSS. 0b013e3181df16d9 20351587
19. Improving Childhood Obesity Treatment Using New Technologies: The ETIOBE System. Baños RM, Cebolla A, Botella C, García-Palacios A, Oliver E, Zaragoza I, Alcaniz M, Clin Pract Epidemiol Ment Health 2011 7 62 66 10.2174/1745017901107010062 21559232
20. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity related liver disease. Mandato C, Lucariello S, Licenziati MR, Franzese A, Spagnuolo MI, Ficarella R, Pacilio M, Amitrano M, Capuano G, Meli R, Vajro P, J Pediatr 2005 147 62 66 10.1016/j.jpeds.2005.02.028 16027697 (Pubitemid 40981147)
21. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE, Aliment Pharmacol Ther 2005 21 871 879 10.1111/j.1365-2036.2005. 02420.x 15801922 (Pubitemid 40477247)
22. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K, Pediatr Diabetes 2009 10 5 13 10.1111/j.1399-5448. 2008.00450.x 18721166
23. Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. Lavine JE, Schwimmer JB, Van Natta ML, JAMA 2011 305 1659 1668 10.1001/jama.2011.520 21521847
24. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. Lavine JE, J Pediatr 2000 136 734 738 10839868 (Pubitemid 30415645)
25. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, Capuano G, Migliaro F, J Pediatr Gastroenterol Nutr 2004 38 48 55 10.1097/00005176-200401000-00012 14676594 (Pubitemid 39274467)
26. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, Lu JR, Wu XM, World J Gastroenterol 2008 14 1598 1602 10.3748/wjg.14.1598 18330955 (Pubitemid 351460179)
27. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P, Hepatology 2008 48 119 128 10.1002/hep.22336 18537181 (Pubitemid 351975537)
28. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Dohil R, Schmeltzer S, Cabrera BL, Wang T, Durelle J, Duke KB, Schwimmer JB, Lavine JE, Aliment Pharmacol Ther 2011 33 1036 44 10.1111/j.1365-2036.2011.04626.x 21395631
29. Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children (CyNCh) http://clinicaltrials.gov.
30. Bile acids as regulators of hepatic lipid and glucose metabolism. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M, Dig Dis 2010 28 220 224 10.1159/000282091 20460915
31. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N, J Pediatr 2000 136 739 743 10839869 (Pubitemid 30415646)
32. Hepatic complications of obesity. Diehl AM, Gastroenterol Clin North Am 2010 39 57 68 10.1016/j.gtc.2009.12.001 20202579
33. Risks of using ursodeoxycholic acid to treat primary sclerosing cholangitis. Volk ML, Gastroenterology 2011 14 2267 2268
34. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R, J Pediatr Gastroenterol Nutr 2011 52 740 743 10.1097/MPG.0b013e31821f9b85 21505361
35. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S, Lipids Health Dis 2011 10 49 10.1186/1476-511X-10-49 21477300
36. Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. Fuchs M, J Lipids 2012 2012 934396 22187656
37. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Musso G, Gambino R, Cassader M, Curr Opin Lipidol 2010 21 76 83 10.1097/MOL. 0b013e3283347ebb 19915460
38. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M, Diabetes Obes Metab 2012 14 112 120 10.1111/j.1463-1326.2011.01483.x 21812894
39. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG, Gut 2001 48 206 211 10.1136/gut.48.2.206 11156641 (Pubitemid 32141844)
40. Probiotics, prebiotics, and synbiotics-approaching a definition. Schrezenmeir J, de Vrese M, Am J Clin Nutr 2001 73 2 Suppl 361S 364S 11246518
41. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high fat diet-induced obesity and diabetes in mice. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R, Diabetes 2008 57 1470 1481 10.2337/db07-1403 18305141
42. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R, J Nutr 2009 139 905 911 10.3945/jn.108.101808 19321579
43. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C, J Clin Gastroenterol 2005 39 540 543 10.1097/01.mcg.0000165671.25272.0f 15942443 (Pubitemid 40863651)
44. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Mastropasqua E, Orando S, Orlando R, Cochrane Database Syst Rev 2007 1 CD005165
45. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J, Eur Rev Med Pharmacol Sci 2011 9 1090 1095
46. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. Parnell JA, Reimer RA, Gut Microbes 2012 1 29 34
47. Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Masterton GS, Plevris JN, Hayes PC, Aliment Pharmacol Ther 2010 31 679 692 10.1111/j.1365-2036.2009.04230.x 20415840
48. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Weiner RA, Dig Dis 2010 28 274 279 10.1159/000282102 20460923
49. Nutritional strategy for adolescents undergoing bariatric surgery: report of a working group of the Nutrition Committee of NASPGHAN/NACHRI. Fullmer MA, Abrams SH, Hrovat K, Mooney L, Scheimann AO, Hillman JB, Suskind DL, National Association of Children's Hospitals and Related Institutions; North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition, J Pediatr Gastroenterol Nutr 2012 54 125 135 10.1097/MPG.0b013e318231db79 21857247
50. Role of toll-like receptors and their downstream molecole in the development of nonalcoholic Fatty liver disease. Miura K, Seki E, Ohnishi H, Brenner DA, Gastroenterol Res Pract 2010 2010 362847 21274430
51. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Kanzler H, Barrat FJ, Hessel EM, Coffman RL, Nat Med 2007 13 552 559 10.1038/nm1589 17479101 (Pubitemid 46830615)
52. GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. Lee J, Hong SW, Rhee EJ, Lee WY, Diabetes Metab J 2012 36 262 267 10.4093/dmj.2012.36.4.262 22950055